The Federal Circuit on July 29, 2011, held in a 2-1 decision that isolated BRCA1/2 DNA molecules used for diagnosing increased breast and ovarian cancer risk are eligible for patent protection under 35 U.S.C. §101. Association for Molecular Pathology v. USPTO, Fed. Cir., No. 2010-1406, 7/29/2011. In addition, the panel unanimously agreed that claims on… Continue reading Isolated DNA Molecules used for Cancer Screening Are Patent Eligible